Nosopharm is a biotech company that is dedicated to discovering and developing innovative therapies to combat infectious diseases, with a particular focus on antimicrobial resistance. With infectious diseases being a leading cause of global mortality, Nosopharm aims to address this critical challenge by creating novel anti-infective therapies. Nosopharm's research and development programs are built upon their unique expertise in the exploitation of two bacteria, Photorhabdus and Xenorhabdus, which have shown potential in producing antimicrobial agents.

As the only biotech company exploring the applications of these bacteria for anti-infective purposes, Nosopharm is at the forefront of groundbreaking discoveries. The company has achieved significant milestones in its history, including the discovery of the Odilorhabdins antibiotic class and the development of NOSO-502, the first clinical candidate of this class. Nosopharm has also entered into prestigious partnerships and consortia, such as ND4BB ENABLE and GNA NOW, dedicated to antibacterial drug development.

Additionally, the company has successfully raised funding to support its research efforts. Nosopharm is led by a team of experienced professionals, including CEO Philippe Villain-Guillot, CSO Maxime Gualtieri, and head of non-clinical development Emilie Racine. Their combined expertise in medicinal chemistry, microbiology, and drug development is instrumental in driving Nosopharm's mission forward.

The supervisory board of Nosopharm is composed of industry veterans, including Jacques Dumas, who has extensive experience in R&D and has co-invented two marketed drugs. Frédéric Hammel and Sandra Dubos, from venture capital firms Elaia Partners and Kreaxi respectively, provide valuable insights and support to the company. With its strong focus on research, innovation, and partnerships, Nosopharm is poised to make significant contributions in the fight against infectious diseases and antimicrobial resistance